Neurocrine Biosciences Inc (NBIX) — Capital Reinvestment Ratio
Latest as of December 2025:
0.01x
Neurocrine Biosciences Inc (NBIX) has a Capital Reinvestment Ratio of 0.01x as of December 2025, meaning it reinvests 0% of its operating cash flow ($388.40 Million) in capital expenditures ($2.40 Million). See cash generation quality of Neurocrine Biosciences Inc to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.01x
Capex / Operating Cash Flow
Operating Cash Flow
$388.40 Million
USD
Capital Expenditures
$2.40 Million
USD
Data as of
Dec 2025
Most recent filing
Neurocrine Biosciences Inc Capital Reinvestment Ratio (1996–2025)
This chart tracks Neurocrine Biosciences Inc's Capital Reinvestment Ratio across 12 annual periods.
Annual Capital Reinvestment Ratio for Neurocrine Biosciences Inc (1996–2025)
Year-by-year Capital Reinvestment Ratio for Neurocrine Biosciences Inc from 1996 to 2025. For live market cap and broader valuation context, see NBIX company net worth.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.04x | $782.70 Million | $34.00 Million | ▼ -32.3% |
| 2024 | 0.06x | $595.40 Million | $38.20 Million | ▼ -11.6% |
| 2023 | 0.07x | $389.90 Million | $28.30 Million | ▲ +49.3% |
| 2022 | 0.05x | $339.40 Million | $16.50 Million | ▼ -46.7% |
| 2021 | 0.09x | $256.50 Million | $23.40 Million | ▲ +91.2% |
| 2020 | 0.05x | $228.50 Million | $10.90 Million | ▼ -52.3% |
| 2019 | 0.10x | $147.00 Million | $14.70 Million | ▼ -59.1% |
| 2018 | 0.24x | $101.40 Million | $24.80 Million | ▲ +3777.7% |
| 2010 | 0.01x | $49.94 Million | $315.00K | ▼ -99.5% |
| 2003 | 1.36x | $37.13 Million | $50.44 Million | ▲ +133.5% |
| 1997 | 0.58x | $11.00 Million | $6.40 Million | ▲ +143.6% |
| 1996 | 0.24x | $6.70 Million | $1.60 Million | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow